



We make healthy possible

FAST-GROWING GLOBAL PHARMACEUTICAL COMPANY & LEADING PROVIDER OF AFFORDABLE MEDICINES



Diversified portfolio of ~270 products across Retail Generics, Injectables, Biosimilars and Specialty



Robust R&D engine generating 39 new retail and injectables product launches in 2023 and 30+ more planned in 2024; focused on high-value, complex products



Expansive R&D, manufacturing and commercial capabilities at scale with vertical integration



Accelerated revenue and profit growth outlook with higher cash flow generation and continued deleveraging

DIVERSIFIED PORTFOLIO DELIVERING SUSTAINABLE GROWTH...



Retail Generics

#4 U.S. Generics portfolio shift to complex dosage forms



Injectables

Expanding portfolio of 30+ institutional products



Biosimilars

Drive portfolio and add more biosimilars to the pipeline



AvKARE

Expanding presence across channels and dosage forms



Specialty

Focus on Neurology and Endocrinology



International

Market expansion in India, Europe, China & rest of world

...WITH KEY CATALYSTS IN 2024 AND BEYOND



Retail Generics

Launched: Lisdexamfetamine, Fluorometholone acetate, Carvedilol ER

Select potential launches: Gx CiproDex®, Mesalamine, and 4 Inhalation/Nasal ANDAs pending, including Naloxone, Gx QVAR® and Gx ProAir®



Injectables

Launched: Potassium phosphate, Calcium gluconate

Select potential launches: PEMRYDI RTU, Methylprednisolone acetate, Exenatide pen injector, Epinephrine, Propofol emulsion, Foscarnet sodium



Biosimilars

In-licensed: 2 denosumab biosimilar pipeline candidates

Look to expand portfolio by in-licensing 2-3 more biosimilars in 2024



Specialty

Potential launches: IPX203 for Parkinson's Disease in Q3'24 and DHE autoinjector for migraine and cluster headache in Q1'25

FINANCIALS⁽¹⁾

\$2.55 – 2.65B

2024 Net Revenue guidance

\$580 – 620M

2024 Adj. EBITDA guidance

+13% CAGR


2019 to 2023 Adj. EBITDA

<4.0x


Net leverage by end of 2025, down from 5.3x at end 2022

ADJUSTED EBITDA GROWTH

\$ in millions



DIVERSIFIED & EXPANDING REVENUE BASE



NASDAQ:

AMRX

Follow Amneal on social at:



All data as of March 1, 2024.

1. Reflects 2024 guidance as of March 1, 2024. Full year 2024 estimates are based on management's expectations for prescription trends, pricing levels, inventory levels, the costs incurred and benefits realized of restructuring activities and the anticipated timing of future product launches and events, among other factors, and does not contemplate one-time and non-recurring items such as legal settlements and other discrete items. Adjusted EBITDA is a non-GAAP measure; a discussion of Non-GAAP measures is included in the press issued on March 1, 2024, available at <https://investors.amneal.com/news/press-releases/>.